Skip to main content
. 2019 Jan 22;22(1):1–14. doi: 10.4048/jbc.2019.22.e6

Figure 2. The interaction of different concepts for tissue-specific tumorigenesis in BRCA1 mutation carriers.

Figure 2

All arrows behind proteins or processes indicate their change of activity in comparison to non-mutated individuals (aromatase ↑ indicates that its activity in mutation carriers is increased). Arrows between proteins or processes indicate whether the interaction increases or decreases the activity of the affected participant (BRCA1 ⟞ aromatase indicates that BRCA1 decreases aromatase's activity; consequently BRCA ↓ ⟞ aromatase ↑ indicates that 1) BRCA1 is decreased in mutation carriers, 2) that it physiologically decreases aromatases activity, and 3) that aromatase's activity is subsequently increased in mutation carriers). Not all concepts are illustrated. For detailed information see text.

ES = estrogen; ER = estrogen receptor; PO = progesterone; PR = progesterone receptor; NF-κB = nuclear factor-κB; NRF2 = nuclear factor (erythroid-derived 2)-like 2; RANKL = receptor activator of nuclear factor-κB ligand; JAG1 = jagged 1; CYP1A1 = cytochrome P450 1A1; SIRT1 = sirtuin 1; SNAI2 = snail family transcriptional repressor 2.